arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Corbus Pharmaceuticals Holdings, Inc.

CRBP
$2.84 ▼ -0.75 (-20.89%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
54 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Corbus Pharmaceuticals Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.1M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -28.0% ↘
FCF / Share $-1.53 ↘
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-35.04M
↓ -98.4% —
FCF / Share Free cash flow per share
$-1.53
↓ -11.7% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
16
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 54 quarters